PCM
NRIX icon

Penserra Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Penserra Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,015
Closed -$30K – 1487
2021
Q3 		$30K Buy
1,015
+5
+0.5% +$154 ﹤0.01% 1182
2021
Q2 		$26K Buy
1,010
+125
+14% +$3.67K ﹤0.01% 1109
2021
Q1 		$27K Sell
885
-5
-0.6% -$189 ﹤0.01% 919
2020
Q4 		$29K Buy
+890
New +$29.5K ﹤0.01% 789

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Penserra Capital Management's NRIX Position: Q4 2021 in Review

Penserra Capital Management sold out of Nurix Therapeutics (NRIX) in Q4 2021, closing a stake of 1,015 shares — an estimated $30K sold.

Penserra Capital Management first reported a position in NRIX in Q4 2020 and held it in 4 quarters. The position peaked at $30K in Q3 2021. 125 funds tracked by Wall St. Rank hold NRIX as of Q4 2021.

  • Penserra Capital Management reported no remaining Nurix Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,015 Nurix Therapeutics shares in Q4 2021, an estimated $30K.
  • Penserra Capital Management first reported a position in Nurix Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Nurix Therapeutics position peaked at $30K in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.